Exploratory subgroup analyses were conducted among NSCLC patients from discovery set that included only patients under first line platinum-based doublet chemotherapy without actionable driver mutations (n = 145) or EGFR wild-type (n = 149). This evidence concerns the gene EGFR and non-small cell lung carcinoma.